Clinical Trials Logo

Citation(s)

Phase II Study of Bevacizumab Plus Irinotecan (Camptosarâ„¢) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

Details for clinical trial NCT00381797